Skip to content
Company Analysis

HUTCHMED (China) Limited HCM

A comprehensive view of key metrics, scores, and financial health for HUTCHMED (China) Limited

Overview of HUTCHMED (China) Limited

HCM NMS
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
HUTCHMED (China) Limited (HCM), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $13.88, about 24.6% overvalued vs fair value, -22.6% 1Y return, placing in the top 25% of its sector.
Metrics P/E 5.1× Rev Growth -13.0% ROE 45.7% Gross Margin 38.7%
USD 13.88
-1.49%
(Delayed)
• Vol 90d: 45.1%
52-Week Range
Market Cap
$1.94B
Enterprise Value
$1.97B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 100%
Confidence: 62%
Updated: Sep 12
Top Beats

Quick Facts

Website https://www.hutch-med.com
HQ Hong Kong
Employees 1,780
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$10
$10
$11
Current: $13.88 -25% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$548.5M
-13%%
Gross Profit
$212.2M
-24.6%%
R&D Expense
$148.3M
-30.1%%
Operating Income (EBIT)
$501.6M
28316.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
-12.9%
Poor

Weak cash conversion - investigate working capital

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating HUTCHMED (China) Limited's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
51
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.92), with robust interest coverage.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.88), providing operational cushion.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 36.2th percentile with high volatility suggests weak pricing power or commoditized products.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.30), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
26
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing HCM's balance between Growth (26.8%), Profitability (31.1%), and Safety (42.2%). Growth 27% Safety 42% Profitability 31%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

52th percentile vs peers
53
Key Signals
EPS Growth YoY 11.11 93p Revenue CAGR 3Y 8.8% 61p Rev Growth YoY -13.0% 17p
Strengths
  • EPS Growth YoY in top 20% of peers (11.11, 93th percentile)
  • Interest Coverage Ratio in top 20% of peers (175.06, 99th percentile)
  • Net Profit Margin in top 20% of peers (83.3%, 99th percentile)
Risks
  • Rev Growth YoY in bottom 20% of peers (-13.0%)

Profitability

61th percentile vs peers
61
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

82th percentile vs peers
83
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for HUTCHMED (China) Limited.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$10.47
- - -
-24.6% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000